TMO
Thermo Fisher Scientific Inc.
$593.92
Earnings Summary
Revenue | $10970Mn |
Net Profits | $1664Mn |
Net Profit Margins | 15.17% |
PE Ratio | 26.75 |
Highlights
Thermo Fisher Scientific Inc.’s revenue jumped 18.3% since last year same period to $10970Mn in the Q2 2022. On a quarterly growth basis, Thermo Fisher Scientific Inc. has generated -7.18% fall in its revenue since last 3-months.
Thermo Fisher Scientific Inc.’s net profit fell -8.97% since last year same period to $1664Mn in the Q2 2022. On a quarterly growth basis, Thermo Fisher Scientific Inc. has generated -24.88% fall in its net profits since last 3-months.
Thermo Fisher Scientific Inc.’s net profit margin fell -23.05% since last year same period to 15.17% in the Q2 2022. On a quarterly growth basis, Thermo Fisher Scientific Inc. has generated -19.07% fall in its net profit margins since last 3-months.
Thermo Fisher Scientific Inc.’s price-to-earnings ratio after this Q2 2022 earnings stands at 26.75.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Thermo Fisher Scientific Inc. post its latest quarter earnings
EPS Estimate Current Quarter | 4.99 |
EPS Estimate Current Year | 4.99 |
Highlights
Thermo Fisher Scientific Inc.’s earning per share (EPS) estimates for the current quarter stand at 4.99 - a 0% jump from last quarter’s estimates.
Thermo Fisher Scientific Inc.’s earning per share (EPS) estimates for the current year stand at 4.99.
Key Ratios
Key ratios of the Thermo Fisher Scientific Inc. post its Q2 2022 earnings
Earning Per Share (EPS) | 5.51 |
Return on Assets (ROA) | 0.08 |
Return on Equity (ROE) | 0.2 |
Dividend Per Share (DPS) | 1.04 |
Highlights
Thermo Fisher Scientific Inc.’s earning per share (EPS) fell -1.61% since last year same period to 5.51 in the Q2 2022. This indicates that the Thermo Fisher Scientific Inc. has generated -1.61% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Thermo Fisher Scientific Inc.’s return on assets (ROA) stands at 0.08.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Thermo Fisher Scientific Inc.’s return on equity (ROE) stands at 0.2.
Thermo Fisher Scientific Inc. declared 1.04 dividend per share during the earnings announcement for Q2 2022.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-07-02 | 4.99 | 5.51 | 10.42% |
2022-05-06 | 6.18 | 7.25 | 17.31% |
Company Information
The Company was the product of a merger between parent companies Thermo Electron & Fisher Scientific in 2006. Among Thermo Electron's product offerings were analytical and laboratory instruments. Its revenues in 2004 totalled $2 billion. Fisher Scientific was founded in 1902. It provides laboratory equipment and associated services. The resultant Company is in the healthcare industry, specialising in diagnostic and research. The Company's segments are life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services. Over the years, 65 companies were acquired by Thermo Fisher Scientific, including 13 in just the past five years. Private equity firms funded approximately 22 acquisitions. Additionally, eight assets were divested. A $17.4 billion acquisition in 2021 was Thermo Fisher Scientific's largest acquisition to date. The most recent acquisitions are Mesa Biotech and the European Viral Vector business. Currently, the Company has more than 4,00,000 customers around the world. It has employed over 75,000 people. North America accounts for more than half of the Company's sales. The Company's core markets are pharmaceuticals, biotechs, diagnostics, health care, academics, and government. It stands in line with companies such as Abbott Laboratories, Becton Dickinson & Agilent Technologies. Currently Thermo Fisher Scientific Inc. has a market cap of $216.11 Billion. It has a P.E ratio of 28.14. The shares of Thermo Fisher Scientific Inc. are trading at $539.82. .
Organisation | Thermo Fisher Scientific Inc. |
Headquarters | Waltham, Massachusetts, US |
Employees | 13K |
Industry | Health Technology |
CEO | Marc Casper |